As the year draws to a close, we’d like to wish all of our customers, partners and friends around the world, a very Merry Christmas. We hope you enjoy the time with your families and best wishes for the New Year!
From everyone at ValitaCell and the team at Beckman Coulter Life Sciences, we wish all of our US friends, customers and colleagues a very happy and safe #thanksgiving2022.
Our partner @moldev have today announced that @valitacell's IgG quantification assay, Valita®Titer, is available for sale across Europe and North America. Read more from Terrell Mathews, Vice President of Global Sales at @moldev here:
https://t.co/Fwazj3xRBy
It's the weekend (almost) so here's some more optimistic news from the Cell and Gene meeting on the Mesa. Can stem cell engineering offer hope for hair loss? Some of us sure hope so! 👴🏻🙏🏻Watch this fun interview here: https://t.co/D9qOZEsxTu
The @US_FDA 's increased workload in the #cellandgenetherapy area has resulted in the establishment of a "super office" to manage the current and anticipated workload. Great to learn about so much activity happening in the space! Read more here: https://t.co/Fw3zLsH4Mv
With nine expert scientific teams in five countries, building partner relationships was crucial for the #Horizon2020-funded @AutoCRAT2020 project team which is working to find a cure for #Osteoarthritis. Read more here: https://t.co/kua0s7w7ch
BioProcess International Boston starts tomorrow, September 27th. Come and meet the ValitaCell and Beckman Coulter Life Sciences team at booth #714 and discover how we can transform your workflows!
Data warehousing is often overlooked by scientific companies in favour of glamour topics such as AI or IoT. ValitaCell argue that good data warehousing is pivotal to successfully digitising bioprocessing businesses and initiatives. Read more here: https://t.co/JN3Y1xfIGd
📢 We're proud to announce that ValitaCell is now part of the Beckman Coulter Life Sciences family! Read our press release here to learn more! https://t.co/DS7Q7TF0TI
Some good news for #celltherapy research as the 1st U.S. patient received autologous stem cell therapy to treat dry AMD which is a leading cause of vision loss among older Americans. Read more from The National Institutes of Health @NIH here: https://t.co/EFUDVyYvWf
@ScienceBoard report that @goteborgsuni scientists have identified a previously unknown mechanism controlling tumor growth in cultured cells and mice. The discovery offers the potential for new targets for cancer treatments. Read more here: https://t.co/iHwcA5ZMzU
Thanks to Tecan for featuring ValitaCell in their latest Tecan journal. Read Dr. Eligio Iannetti's interview and learn more about what we are doing to improve speed, accuracy and performance for bioprocessing. Read the full interview here: https://t.co/lqnVdIIcMK
@CHI_Healthtech's Bioprocessing Summit takes place next week in Boston from August 15th to 18th. Meet @valitacell at booth #410 and say hello to the team. Discover our pioneering Quantum, CellAi® and ChemStress® technologies. See you there!
An interesting read from the @ScienceBoard who report that even the most exhausted T cells can be revived according to the University of Pittsburg @PittTweet Medical Center researchers. Read more here: https://t.co/CT5DoxOYRW
17 new animal health drugs have been approved by the @US_FDA so far in '22 including @Zoetis Solensia #monoclonalantibody therapy for feline #osteoarthritis. Download our tech note to learn how Valita®Titer can be used in canine IgG screening programmes: https://t.co/m9YxHFa9tT
The animal healthcare market is valued at $40bn annually. Advancements in human pharma are transferring to animal health and mAbs are now becoming more established. As the market grows, what role will advanced analytics play? Read our latest blog here: https://t.co/S3LO478Rle
We're hiring: We've seen some great potential candidates over the past few weeks but there is still time to apply for open roles in our biologics, cell therapy and artificial intelligence teams. Find out more about our openings here: https://t.co/Ftl4kmwi6e